PFS was significantly longer in the FOLFOX4 with cetuximab group compared with UFOX with cetuximab group ( median 8.2 vs. 6.6 months ; hazard ratio , 0.68 ; 95 % confidence interval [ CI ] , 0.52-0 .89 ; P = .0048 ) .